Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Great Care for Common Conditions: Combining Evidence and Cost Effectiveness - Urticaria
Description
The talk focuses on urticaria, a common condition affecting a significant number of individuals, with specific emphasis on its types and treatment strategies. Acute urticaria typically lasts less than six weeks, while chronic urticaria persists longer and can severely impact quality of life due to associated itching. Most cases, especially chronic ones, often remain idiopathic, with limited success in identifying underlying causes. Current treatment guidelines recommend escalating doses of second-generation antihistamines before considering the use of omalizumab, the only approved biologic for chronic spontaneous urticaria, which retains efficacy in about 60% of cases. For refractory patients, cyclosporine may be considered, albeit with caution regarding long-term use. Novel therapeutic targets are being explored, including BTK inhibitors and dupilumab, which may provide rapid symptomatic relief. Cost-effectiveness analyses suggest that treatments for chronic urticaria, including omalizumab, are financially justifiable given their impact on overall healthcare costs through improved productivity and reduced medical visits. Furthermore, the potential emergence of new treatments holds promise, catering to patients with varying phenotypes of urticaria and emphasizing the need for tailored therapeutic approaches in management.
View moreConclusions
- Urticaria is common, with 10-20% of people experiencing it at some point in their lives, but chronic cases are much rarer.
- Acute urticaria has a high chance of spontaneous remission (90%), while chronic urticaria has a less favorable prognosis, lasting on average over 5 years.
- Most cases of urticaria of any type have no identifiable cause, complicating treatment efforts.
- Current treatment guidelines recommend starting with second-generation antihistamines, increasing dosages as necessary, and considering add-on therapies for inadequately controlled chronic urticaria.
- Omalizumab is an effective biological treatment for those unresponsive to antihistamines but does not work for all patients; around 40% of patients may not respond adequately.
- Cyclosporine can be effective in cases where other treatments fail, but there are safety considerations and monitoring requirements.
- Emerging therapies and biologicals show promise, but further research is needed to establish efficacy, safety, and cost-effectiveness.
- Routine laboratory tests are generally not useful in managing chronic urticaria and should not be conducted unless clinically indicated; this approach is endorsed by the 'Choosing Wisely' campaign.
- Our analysis indicates that treatments like omalizumab are cost-effective in managing chronic urticaria despite their higher upfront costs, adding to the rationale for their use in refractory cases.
- 1254 ZUBERBIER, BERNSTEIN, AND MAURER, J ALLERGY CLIN IMMUNOL, DECEMBER 2022
- Lang et al. Ann Allergy Asthma Immunol May 2011
- Surapon Nochaiwong, PharmD; Mati Chuamanochan, MD; Chidchanok Ruengorn, PhD; Ratanaporn Awiphan, PhD; Jonathan A. Bernstein, MD; Kednapa Thavorn, PhD, JAMA Dermatology | Review, Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria, A Systematic Review
- Pedro Mendes-Bastos 1, Ana Brasileiro 2 3, Pavel Kolkhir 4 5 6, Stefan Frischbutter 4 6, Jörg Scheffel 4 6, Sherezade Moñino-Romero 4 6 , Marcus Maurer 4 6, Review > Allergy. 2022 Aug;77(8):2355-2366. doi: 10.1111/all.15261. Epub 2022 Feb 28.